AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$CRL

FOSTER JAMES C sold $10.1M of CRL

FOSTER JAMES C sold 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $300.00 ($10.07M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FOSTER JAMES C
Published Aug 27, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRL
Bearish
medium confidence
Mentioned
$CRL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which traders may use to adjust short‑term positions.

02

Market read

Insider sell of $10M by a director is a modestly material event for CRL, offering a low‑to‑moderate trading signal.

03

What to watch

Potential upcoming earnings or product news that could offset the sell pressure.

Relevance 6/10Novelty 8/10Timing: post‑market 2026‑08‑25

Background

Form 4 filings disclose insider transactions and are primary sources of new corporate information.

Company-level read

Ticker impact

$CRLBearishMedium confidence
Context

Director Foster James C sold 33,561 shares for $10.07M via a 10b5‑1 plan on 2026‑08‑25.

Expected impact

Potential modest downside pressure in the next trading session.

Evidence & confidence

A $10M sale by a director is material for a mid‑cap biotech, but not large enough to trigger a major move.

Market effects

Sector

May raise concerns for the biotech services sector if other insiders follow suit.

Regional

Limited to US markets where CRL trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory services and products to the pharmaceutical and biotech industries.

  • Individual
    Foster James C.

    Director of Charles River Laboratories who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min